Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure Biosciences preps for up-list on US exchanges after Q1 earnings

Pressure Biosciences laid out its 2016 goals on Wednesday which include implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT
Pressure Biosciences preps for up-list on US exchanges after Q1 earnings
Seeks distribution partner for the Barozyme HT48 high throughput system

Pressure Biosciences Inc (OTCMKTS:PBIO) laid out its 2016 goals on Wednesday which include implementation of financial self-sufficiency and future growth and profitability as well as preparation for a targeted up-list to NASDAQ or the NYSEMKT.

The company also wants to complete the manufacture of the Barocycler 2320 EXTREME and begin the commercialisation phase for this computer-driven, new pressure-generating instrument during the second quarter, as well as secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.

The near-term goals accompanied the company reporting its first quarter earnings results which saw products and services revenue increases 26% year-on-year to $510,478 and sales of Instruments and Consumables rise to $454,350 from $359,364.

Pressure BioSciences develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn life sciences sample preparation market.

The company recorded a net loss of $5.95mln in the three months to March 31, from $2mln in the same period a year ago.

"We believe the market for our pressure-based products (instruments and consumables) is large, diverse, and growing.  In order to successfully increase and expand our penetration into this market, it is essential that we continue to increase market exposure and acceptance of our novel PCT-based product line," said Richard T. Schumacher, President and CEO of PBI.

"We believe the major operational accomplishments of the 2016 first quarter – especially the co-marketing agreement with SCIEX and the development of the new Barocycler 2320EXTREME – will play key roles in increasing our visibility, acceptance, and success in penetrating this market, which will subsequently help PBI achieve rapid and dramatic growth in the near future," he added.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1527682514_angel-delight.jpg
May 30 2018
The latest fundraiser underscores the fact the life sciences business is well supported in the City
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use